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Kimura disease (KD) is a chronic inﬂammatory disorder that
presents as painless lymphadenopathy or subcutaneous masses,
most predominantly in the head and neck region. Peripheral eosin-
ophilia and elevated serum IgE levels are the characteristics of the
disease. Promoted helper type 2 (Th2) responses are suggested to
be the mechanism underlying KD. Although the disease has a
benign course, relapse often occurs after the ﬁrst-line therapy,
which includes surgical excision, radiotherapy, and topical steroids.
Recently, cyclosporine A (CsA) for the treatment of recurrent KD has
been reported. Here, we describe a patient with recurrent KD after
surgical and medium-dose steroid therapy who was successfully
treated with low-dose (2 mg/kg/d) CsA. We also review the litera-
ture related to CsA treatment for KD.
A 25-year-old Japanese man with a childhood history of atopic
dermatitis presented with a left buccal soft tumor (Fig. 1A). At the
age of 11 years, he had been diagnosed as having KD on the basis
of biopsy ﬁndings for a left buccal tumor. At the age of 16 years, he
had undergone surgical excision of the tumor, followed by oral
steroid therapy. Although he had remained in remission for 1
year, after discontinuation of the oral steroid, the tumor had again
grown in size, to that of a goose egg. He was referred to the otorhi-
nolaryngology department for surgical excision of the tumor
again; this time, however, the tumor could not be excised owing
to an ambiguous margin between the tumor and the normal tissue
that was due to the progression of ﬁbrosis. He was prescribed
50 mg/d (0.7 mg/kg/d) of oral prednisolone (PSL) after the surgical
biopsy, followed by tapering by 10% every 4 days. After the dose of
PSL was tapered to 30 mg/d, the tumor reduction ceased, and he
was subsequently referred to our internal medicine department.
The laboratory ﬁndings revealed an increased leukocyte count of
15,200/mm3 with hypereosinophilia (eosinophils: 10,792/mm3
[71%]); hemoglobin: 17.4 g/dl; and platelets: 241,000/mm3. C-reac-
tive protein was negative and the erythrocyte sedimentation rate
was normal. The urinalysis and kidney function were also normal.
He had extremely elevated serum IgE levels (6519 mg/dl) when
taking 30 mg/d of oral PSL. Soluble IL-2 receptor was elevated to
952 U/ml and IgG4 was within normal range. In this case, the
serum levels of Th2 cytokines such as IL-4, IL-5, and IL-13 were
below detection limits. Magnetic resonance imaging revealed a
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with multiple swollen lymph nodes around the left cervical re-
gion. Histologic examination of a biopsy sample from the tumor
showed a proliferation of lymphoid follicles with germinal center
formation. Eosinophils inﬁltrated the interfollicular spaces with
some eosinophilic granulomas (Fig. 1E). Immunohistochemical
staining showed c-kitþ mast cells around the follicles and abun-
dant IgE deposition in the lymphoid follicles (Fig. 1E). KD relapse
was diagnosed, and the oral PSL dose was subsequently increased
from 30 mg/d to 50 mg/d, again followed by slow tapering by 10%
every 2 weeks. The eosinophilia, hyper IgE and the left buccal tu-
mor improved soon after oral PSL was increased (Fig. 1F); however,
the mass re-grew after PSL was tapered to 30 mg/d. Therefore, PSL
was increased from 30 mg/d to 40 mg/d again and 150 mg/
d (2 mg/kg/d) of oral CsA was added for the refractory tumor. After
the start of oral CsA, the total serum IgE levels continually
decreased from 1026 mg/dl to 400 mg/dl (Fig. 1F). The serum
trough concentration of CsA was around 80 ng/ml. During the 11
months in which the PSL dose was tapered to 10 mg/d, he experi-
enced no recurrence of the tumor (Fig. 1C, D). For the use of CsA
for the treatment to KD, informed consent from the patient and
approval from the local ethics committee were obtained (H27-
173, University of Tsukuba Hospital).
KD is a chronic inﬂammatory disorder that presents as painless
lymphadenopathy or subcutaneousmasses with pathologic charac-
teristics of eosinophilic inﬁltration of the interfollicular spaces. It
most commonly occurs in young or middle-aged men in Asian
countries.1 Normally the effects of the disease are local and the
overall prognosis is good; however it is sometimes accompanied
by systemic complications such as nephrotic syndrome.1 Although
the etiology of KD is still unknown, it has been suggested that an
allergic mechanism may contribute to its pathogenesis.2 The levels
of IgE, Th2 cytokines such as IL-4, IL-5, and IL-13, thymic stromal
lymphopoietin (TSLP) are elevated in the peripheral blood or pa-
rotid grand tissues of KD patients.2,3 Recurrence of the disease
frequently occurs after surgical, radiation, or steroid therapy and
even during steroid therapy after the dose has been reduced, which
is known to occur in about 25%e40% of cases.4 Chen et al. reported
that younger onset age and a high peripheral blood eosinophil
count were signiﬁcantly associated with disease recurrence, and
also that the eosinophil count was related to the size of the mass
and the therapeutic response.4 Recently, immunosuppressant ther-
apy including CsA or anti-IgE antibody (omalizumab) has been re-
ported to be effective for recurrent KD patients.5e12 CsA inhibits
calcineurin, which leads signaling of the transcription of the IL-2vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
Fig. 1. A. Subcutaneous mass in the left buccal area. B. Magnetic resonance imaging (MRI) showing a 75  135  145 mm mass with partial high signal intensity accompanied with
low signal intensity septum in the left buccal area (T2 Short TI inversion Recovery, Axial view (right panel) and Coronal view (left panel)). C, D. Subcutaneous mass dramatically
reduced after addition of cyclosporine A. E. The mass biopsy shows follicular hyperplasia (hematoxylin and eosin, 100, left upper panel), eosinophilic abscess in the interfollicles
(hematoxylin and eosin, 400, right upper panel). Immunohistochemical staining shows c-kit positive mast cell inﬁltration around follicles (c-kit staining, 100, left lower panel),
and strong IgE deposition in germinal center of the lymphoid follicles (IgE staining, 100, right lower panel). F. The time course of eosinophil count and total serum IgE levels before
and after cyclosporine A treatment. Eos, eosinophil; CsA, cyclosporine A; PSL, prednisolone.
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IL-2 inhibits T cell proliferation and suppresses T cell-mediated im-
mune responses.8,9 Indeed, CsA suppresses the levels of IL-4, IL-5,
IL-13, and ECP in the lymph nodes and serum of KD patients.2,8
Our search of the PubMed database revealed 8 cases of KD
treated with CsA (7 reports) published to date (Table 1). In 5 of
the 8 cases, CsA was used for combined therapy with steroids to
induce re-remission after relapse of the disease. Kaneko et al. and
Nakahara et al. reported that they successfully treated patients
with CsA monotherapy for induction or for relapse.5,6 The initial
dose of CsA was usually 3e5 mg/kg/d.5,8 Notably, Katagiri et al.reported that mRNA levels of Th2 cytokines and eosinophils were
fully suppressed when the concentration of CsA in blood was
75 ng/ml in their patient.2 Monitoring of the serum concentration
of CsA is recommended during induction therapy. In our patient,
2 mg/kg/d of low-dose CsA (trough concentration of 80 ng/ml)
was effective for the tumor, which was refractory to 30 mg/d of
PSL, and we could taper the PSL dose while concomitantly using
CsA. For the maintenance of remission, a reduced dose of CsA (to
2 mg/kg/d) could maintain remission without corticosteroids.10,11
On the other hand, discontinuation of CsA often leads to relapse
of the disease.9e11 Interestingly, Kaneko et al. reported a case in
Table 1
Case of KD treated with CsA.
Author (Year) Age/Sex complications For induction For relapse For maintenance Recurrence
(during maintenance)
PSL CsA PSL CsA PSL CsA
Kaneko et al, (1999) 29/F   5 mg/kg    Off None for 18M
Nakahara et al, (2000) 11/M Nephrotic synd. 2 mg/kg   5 mg/kg  5 mg/kg None
Dede et al, (2005) 21/M Nephrotic synd. 1 mg/kg 5 mg/kg   10 mg/qod 4 mg/kg None
Sato et al, (2006) 11/M  þ  40 mg/d 4 mg/kg 5 mg/qod 4 mg/kg None
Maleki et al, (2010) 25/M Asthma 1 mg/kg  þ 400 mg/d ND 25 mg/d None for 6M
Soeria et al, (2011) 17/M Nephrotic synd. 1 mg/kg  þ 4 mg/kg Off 2 mg/kg None for 4Y
9/M  2 mg/kg  1 mg/kg þ Off þ None
Beccastrini et al, (2013) 40/M  25 mg/d 3 mg/kg 25 mg/d 3 mg/kg Off 2 mg/kg None for 5Y
Present case (2015) 25/M  50 mg/d  40 mg/d 2 mg/kg 10 mg/d 2 mg/kg None for 11M
, None; þ, Yes; Y, Year; M, Month; d, day.
PSL, Prednisolone; CsA, Cyclosporine A; qod, every other day; ND, not described.
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disease for 18 months after the initial CsA monotherapy.5
We have here described a patient with recurrent, massive, and
inoperable KD, whowas resistant to medium-dose PSL but success-
fully treated with low-dose (2 mg/kg/d) CsA. Early low-dose CsA
combined with a corticosteroid might be a promising therapeutic
option for recurrent and refractory KD.
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